eligibility_summary
Adults 18-80 with histologically confirmed relapsed/refractory DLBCL, ECOG 0-2, measurable disease, adequate organs, >=1 prior systemic therapy, relapse after ASCT allowed (>6 mo). Provide recent/fresh tumor tissue, use contraception, life expectancy >=6 mo, consent. Exclude: primary CNS lymphoma, prior BTK inhibitor, major cardiac disease/LVEF<50%, key lab abnormalities, active HIV/HCV or uncontrolled HBV, significant GI disease, pregnancy/lactation, recent therapy/surgery, or CYP3A modifiers.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm study of ZPR (zanubrutinib + polatuzumab vedotin + rituximab) in relapsed/refractory DLBCL. Zanubrutinib: oral, covalent small-molecule BTK inhibitor that blocks B-cell receptor signaling (BTK/NF-κB/PI3K-AKT), suppressing malignant B-cell survival. Polatuzumab vedotin: antibody-drug conjugate to CD79b, binding leads to internalization and release of MMAE (microtubule inhibitor) causing cell-cycle arrest and apoptosis. Rituximab: chimeric anti-CD20 monoclonal antibody that depletes B cells via ADCC, complement, and direct apoptosis. Targets: CD79b+ and CD20+ DLBCL cells, BCR/BTK pathway, microtubules, immune effector mechanisms.